Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-02), Recursion Pharmaceuticals's 3-1 Month Momentum % is -20.84%.
The industry rank for Recursion Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
RXRX's 3-1 Month Momentum % is ranked worse than 71.5% of 1386
companies
in the Biotechnology industry
Industry Median: -9.25
vs RXRX: -20.84
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Recursion Pharmaceuticals 3-1 Month Momentum % Related Terms
RXRX vs NTLA, SEPN, DMRA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Recursion Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recursion Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Recursion Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recursion Pharmaceuticals (RXRX) has a 3-1 Month Momentum % of -20.84% as of Sep. 02, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Recursion Pharmaceuticals and its competitors. According to the industry distribution chart, Recursion Pharmaceuticals ranks #991 out of 1386 companies in the Biotechnology industry, placing it in the top 71.5%.
Is Recursion Pharmaceuticals' 3-1 Month Momentum % too high?
Recursion Pharmaceuticals' current 3-1 Month Momentum % is -20.84%. Based on the distribution chart, Recursion Pharmaceuticals ranks #991 out of 1386 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Recursion Pharmaceuticals has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' 3-1 Month Momentum % compare to NTLA and SEPN?
According to the Biotechnology industry distribution chart, Recursion Pharmaceuticals ranks #991 out of 1386 companies for 3-1 Month Momentum %. This places Recursion Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current 3-1 Month Momentum % is -20.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Fairly Valued. The stock's GF Value™ is $3.10, compared to a current price of $3.32 — trading 7.1% above its estimated fair value. The current 3-1 Month Momentum % is -20.84%. Recursion Pharmaceuticals' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current 3-1 Month Momentum % is -20.84% as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?
Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be overvalued.
The current stock price of $3.32 is trading 7.1% above its estimated GF Value™ of $3.10.
GuruFocus considers Recursion Pharmaceuticals to be Fairly Valued.
Key valuation signals for RXRX:
3-1 Month Momentum %: -20.84%
GF Value™: $3.10 vs. price of $3.32 (7.1% above fair value)
No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
66GF Score
Get the complete analysis for RXRX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RXRX has been successfully added to your 
